Separation Systems for Commercial Biotechnology
The global market for commercial biotechnology separation systems reached nearly $16 billion in 2012 and is expected to reach $17.1 billion by the end of 2013. The market is expected to grow at a compound annual growth rate (CAGR) of 10.1%, reaching a value of $27.8 billion by 2018.
- An overview of the global market for the commercial applications of biotechnology separation systems by product, by company, and by geographic region.
- Analyses of global market trends, with data from 2008 to 2012, estimates for 2013, and projections of compound annual growth rates (CAGRs) through 2018.
- Examination of the various segments of the market, new applications for separation technology, and overall industry trends, as well as the separation process for a variety of biomolecules, including proteins, RNA, and DNA.
- Identification of one of the major drivers for the separations system market: the development by the biomedical and pharmaceutical industries of proteins that can be used as biotherapeutic agents against a number of human diseases; another factor that will contribute to growth is the recognition of this technology in emerging markets such as Japan and the Pacific Rim countries.
- Assessments of trends based on a number of parameters, including projected sales for existing products, new product introductions, and expanded indications for existing products.
Current and projected protein and biomolecule separation revenue forecasts during the forecast period (i.e., 2013 to 2018) are discussed. Protein separation systems are playing important roles in new biopharmaceutical development. Protein separation systems do not require U.S. Food and Drug Administration (FDA) approval, but the products produced from these processes do, and they must be produced in accordance with FDA good manufacturing practices (GMP) guidelines. Thus, these separation procedures and equipment must pass FDA audits of the manufacturing process. New products requiring separation technologies that have been approved by the FDA in 2011 and 2012 are covered, and those products expected to be approved within the forecast period are discussed. Due to the timing of the writing of this report, the figures for 2013 are estimated except where actual results have been reported.
The report includes analysis of the leading competitors, as well as emerging companies in the current global biomolecule separation market. Profiles of the manufacturers of the leading products are analyzed, and their specific product strategies are outlined. This report notes companies that are poised to introduce new products during the forecast period and discusses how these products may change the face of the competitive environment. This competitive environment is examined with a special focus on the ways in which developing products and technologies are influencing the current standard of patient care. Detailed profiles of the current market leaders and emerging companies are discussed in detail.
Market figures are based on revenues at the manufacturers’ level. The base year for analysis and projection is 2013. Trends are assessed based on a number of parameters, including projected sales for existing products, new product introductions and expanded indications for existing products.
This report also includes overviews and forecasts of the separations market by product, by company and by geographic region through 2018. The global market is analyzed, and data are provided for each segment.
When considering flow cytometry values, the numbers cited and projected do not include clinical applications, as clinical applications have been defined as falling outside the biotechnology scope of this report.
Sales figures are reported in U.S. dollars and reflect currency fluctuations within the performance of revenue change. Revenue figures do not account for variation in local currencies.
All market share data are presented on a global basis unless specifically noted.
Jackson Highsmith is a life sciences research consultant with more than 16 years of research experience. Jackson has been consulting with specialty pharmaceuticals and large pharmaceutical industry players since 2007. Prior to that, he worked at a large research consultancy where he focused on in-depth research; he also has worked at a large pharmaceutical company dealing with a wide range of medical therapeutics in early and midstage drug development.